Literature DB >> 24842352

A malignant eccrine spiradenoma of the scalp.

Whitney Chow1, Mat Griffiths1.   

Abstract

Malignant eccrine spiradenoma (MES) is an extremely rare but aggressive tumour, resulting in high mortality. We report the first case in the UK of metastatic MES on the scalp of a 37-year-old man who initially presented with a raised nodular mass which had grown rapidly over a few months. Excision biopsy of the lesion was performed and histology confirmed MES with evidence of cytological atypia and necrosis. A further wide local excision of the lesion with a 1 cm surgical margin was performed and full clearance was achieved. At 10-month follow-up another similar lesion had developed close to the previously excised area. A CT scan demonstrated metastatic lesions in the lungs, liver and pelvis, and subsequently chemotherapy was initiated. Although MES is uncommon, it has a high propensity to metastasise, therefore prompt identification, treatment and close follow-up of these tumours is essential. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24842352      PMCID: PMC4039856          DOI: 10.1136/bcr-2013-202524

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  De novo malignant eccrine spiradenoma: a case report and review of the literature.

Authors:  Basil M Hantash; Joanna L Chan; Barbara M Egbert; Hayes B Gladstone
Journal:  Dermatol Surg       Date:  2006-09       Impact factor: 3.398

Review 2.  Giant malignant eccrine spiradenoma of the scalp.

Authors:  M Jamshidi; M A Nowak; Y T Chiu; E A Perry; S M Fatteh
Journal:  Dermatol Surg       Date:  1999-01       Impact factor: 3.398

Review 3.  Malignant eccrine spiradenoma: a case report and review of the literature.

Authors:  M Ishikawa; Y Nakanishi; N Yamazaki; A Yamamoto
Journal:  Dermatol Surg       Date:  2001-01       Impact factor: 3.398

4.  Malignant transformation of eccrine spiradenoma.

Authors:  M Dabska
Journal:  Pol Med J       Date:  1972

5.  Response of eccrine adenocarcinoma to tamoxifen.

Authors:  K S Sridhar; P Benedetto; C L Otrakji; K K Charyulu
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

Review 6.  Malignant eccrine spiradenoma: a previously unreported presentation and review of the literature.

Authors:  A C Beekley; T A Brown; C Porter
Journal:  Am Surg       Date:  1999-03       Impact factor: 0.688

Review 7.  Malignant eccrine spiradenoma. Case report and review of the literature.

Authors:  J S Tay; E M Tapen; P G Solari
Journal:  Am J Clin Oncol       Date:  1997-12       Impact factor: 2.339

Review 8.  Malignant eccrine spiradenoma of the scalp.

Authors:  Tamer Seyhan; Hüseyin Borman; Nebil Bal
Journal:  J Craniofac Surg       Date:  2008-11       Impact factor: 1.046

9.  Spiradenocarcinoma of the scalp.

Authors:  Brian W Russ; Jeffrey Meffert; Richard Bernert
Journal:  Cutis       Date:  2002-06

Review 10.  Adnexal carcinomas of the skin.

Authors:  S A Marenda; R A Otto
Journal:  Otolaryngol Clin North Am       Date:  1993-02       Impact factor: 3.346

  10 in total
  1 in total

Review 1.  Direct intracranial invasion of eccrine spiradenocarcinoma of the scalp: a case report and literature review.

Authors:  Yuji Kibe; Kuniaki Tanahashi; Kazuhiro Ohtakara; Yuka Okumura; Fumiharu Ohka; Kazuhito Takeuchi; Yuichi Nagata; Kazuya Motomura; Sho Akahori; Akihiro Mizuno; Hiroo Sasaki; Hiroyuki Shimizu; Junya Yamaguchi; Tomohide Nishikawa; Kenji Yokota; Ryuta Saito
Journal:  BMC Neurol       Date:  2022-06-18       Impact factor: 2.903

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.